Hosted on MSN22h
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 Years
SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
BioSpace7d
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers
Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...
Drugmaker shut down after black schmutz found in injectable weight-loss drug
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
BioPharma Dive4d
Viking data provide latest test of oral obesity drug potential
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...
Eli Lilly isn't selling as much Zepbound as expected — and the stock is sinking
Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
NBC 10 Philadelphia9d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...